Search results
Results from the WOW.Com Content Network
The fund draws its name from the acronym for operating system (OS), the software that underlies the basic functions of computers and provides a foundation for other applications. [ citation needed ] OS Fund focuses on investment in technologies and platforms in genomics , synthetic biology , computationally derived therapeutics, advanced ...
Zymergen was founded in 2013. [5] by investment banker Joshua Hoffman, biophysicist Zach Serber, and biochemist Jed Dean. [6]All three met while working at Amyris, Inc. [7] The company uses machine learning and artificial intelligence to study and modify microbes which ferment carbon [6] to produce chemicals used in manufacturing consumer goods and pharmaceuticals. [8]
LS-9 Inc was a venture-funded company focused on producing diesel fuel from transgenic organisms. It launched in 2005, took in $81 million in investment, and in 2013 was sold to Renewable Energy Group for $40 million in cash and stock, and an additional $21.5 million if technology and production milestones were met.
Advances in genetic engineering and synthetic biology are making resurrecting animals once lost to this world a tangible prospect. The organizations and companies at the forefront of de-extinction ...
Synthetic biology, or breaking down life into its basic component parts to create enhanced biological systems, can be likened to writing software that enables life. Or genetic engineering on steroids.
The field of synthetic biology has not been good to investors. But maybe we've just been looking in the wrong places. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 ...
In January 2016, the company received an investment from the Bill & Melinda Gates Foundation's Strategic Innovation Fund to support the development of antimalarial medication based on semi-synthetic artemisinin. [8] In April 2019, the company raised $34-million in private placement of its common stock and warrants.
The fund aimed to raise $100 million [4] however, citing a strong interest, the first fund raise was $160 million, and the firm now has over $2 billion under management. [ 5 ] [ 2 ] [ 12 ] [ 10 ] In December 2017, Michael Pellini, the former CEO and standing Chairman of Foundation Medicine joined S32 as a Managing Partner.